知镜 Cognispect · 医学文献与研究工作台

Future scenarios of radioligand therapy in pheochromocytomas and paragangliomas.

Pacella S, Elisei F, Mattoli MV, Airò Farulla LS, Aliberti G, Rizzo A, Maccauro M.
EJNMMI reports · 2026-09-21 · PMID 42764321

文献摘要

Background Pheochromocytomas and paragangliomas (PPGL) are rare and heterogeneous neuroendocrine tumors for which therapeutic options remain limited, particularly in the metastatic or progressive setting. Radioligand therapy (RLT) has emerged as a promising strategy, leveraging tumor-specific molecular targets to deliver cytotoxic radiation. Objective This review provides a structured and updated overview of RLT in PPGL, critically comparing the two main therapeutic radiopharmaceuticals-[ 131 I]mIBG and [ 177 Lu]Lu DOTATATE-and discussing their clinical evidence, safety profiles, patient selection criteria, and positioning within current guidelines. Emerging approaches, including alpha emitter-based therapies and novel theranostic targets, are also explored. Methods A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science (updated to August 2024), focusing on studies evaluating RLT in PPGL. Due to heterogeneity in study design, protocols, and outcome measures, a metaanalysis was not feasible. Results Evidence derives predominantly from small retrospective studies and a limited number of prospective cohorts. Both [ 1 3 1 I]mIBG and [ 1 7 7 Lu]LuDOTATATE demonstrate favorable safety profiles and high disease control rates, although with substantial variability in protocols and patient populations. Comparative analyses suggest longer progressionfree survival with PRRT in selected patients, particularly those with high somatostatin receptor expression. Conclusions RLT represents a valuable therapeutic option for patients with progressive or symptomatic PPGL. Advances in molecular imaging, alphaemitter therapies, and personalized dosimetry are expected to further refine treatment selection and improve outcomes. Larger prospective studies are needed to define optimal sequencing and integration into clinical practice.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。